Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Australian Household Spending Dips in December as RBA Tightens Policy 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Australian Pension Funds Boost Currency Hedging as Aussie Dollar Strengthens 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
Celltrion, the South Korean pharmaceutical company, revealed that it had sealed its first deal for shipments of its Rekirona COVID-19 antibody treatment. The firm made the announcement on the supply transaction to Pakistan on Monday, May 10.
Celltrion’s Healthcare division will be managing its overseas business, so it was the company affiliate that signed the deal with Pakistan’s state-run company. The first order is for the shipment of 100,000 vials of Rekirona, which is enough for 30,000 people.
Rekirona receives approval from S. Korea’s drug safety board
As per The Korea Herald, once the vials of the COVID-19 antibody treatment have been delivered, Celltrion will also send its experts to Pakistan so they can train the local medical healthcare providers who have been assigned to administer the treatment.
In February, Celltrion’s Rekirona already received conditional approval from the drug safety board in S. Korea. With that, the medication effectively became the first locally-made treatment for coronavirus.
The treatment has been given to around 2,700 high-risk patients, which include individuals who are over 60 years of age. People with chronic diseases that affect the respiratory system were also administered with Rekirona earlier this year, and the results seem promising, or it will not be approved.
Celltrion already completed the third phase of clinical trials that was conducted in 13 countries with 1,300 volunteers. Aside from S. Korea, some of these nations are the U.S. and Spain. Now, the pharma company is hoping that its Rekirona will be able to help stop the growing number of patients in Pakistan.
Celltrion starts global rollout of its COVID-19 treatment
Yonhap News Agency reported that it is not just Pakistan that will have Celltrion’s Rekirona as there are also ongoing negotiations for supply to Europe, U.S., and more. The exports will start in Pakistan, and the distribution will eventually spread to other nations.
"Talks are also currently underway to export Rekirona to other countries in Europe and South America, as well as India," an official from Celltrion said. Meanwhile, two other pharmaceutical companies are developing similar monoclonal antibody treatment, and these are the US-based Regeneron and Eli Lilly. These are still under clinical tests, so it makes Celltrion the first to make a COVID-19 treatment available globally.
